GlassScriptPhysician profile
Dilprit Bagga
NPI 1427262757
$9,406.53
in general payments reported to CMS, 2019-2025
48 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $430 · 2021: $331 · 2022: $270 · 2023: $950 · 2024: $2,384 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,186.16 |
| Education | $455.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,528.57 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $739.77 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $627.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $623.42 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $577.02 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Seagen INC. | $571.98 | 2019-2023 | Adcetris |
| Celgene Corporation | $398.64 | 2023-2025 | Reblozyl, Opdualag |
| Amgen INC. | $316.71 | 2019-2025 | Kyprolis, Evenity, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $312.04 | 2019-2024 | Fruzaqla |
| Astellas Pharma US INC | $266.94 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Genzyme Corporation | $266.06 | 2019-2025 | |
| Gilead Sciences, INC. | $243.17 | 2023-2025 | Trodelvy |
| Abbvie INC. | $241.22 | 2019-2025 | |
| Eisai INC. | $224.55 | 2020-2025 | |
| Lilly USA, LLC | $219.06 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilprit Bagga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.